{
    "root": "34b8266e-fda9-2080-e063-6294a90a91b4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fluoxetine",
    "value": "20250509",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FLUOXETINE HYDROCHLORIDE",
            "code": "I9W7N6B1KJ"
        }
    ],
    "indications": "fluoxetine capsules indicated treatment : acute maintenance treatment major depressive disorder [ ( 14.1 ) ] . acute maintenance treatment obsessions compulsions patients obsessive compulsive disorder ( ocd ) [ ( 14.2 ) ] . acute maintenance treatment binge-eating vomiting behaviors patients moderate severe bulimia nervosa [ ( 14.3 ) ] . acute treatment panic disorder , without agoraphobia [ ( 14.4 ) ] . fluoxetine capsules olanzapine combination indicated treatment : acute treatment depressive episodes associated bipolar disorder . treatment resistant depression ( major depressive disorder patients , respond 2 separate trials different antidepressants adequate dose duration current episode ) . fluoxetine capsules monotherapy indicated treatment depressive episodes associated bipolar disorder treatment treatment resistant depression . using fluoxetine capsules olanzapine combination , also refer section package insert symbyax ® .",
    "contraindications": "indication adult pediatric mdd ( 2.1 ) 20 mg/day ( initial dose ) 10 20 mg/day ( initial dose ) ocd ( 2.2 ) 20 mg/day ( initial dose ) 10 mg/day ( initial dose ) bulimia nervosa ( 2.3 ) 60 mg/day panic disorder ( 2.4 ) 10 mg/day ( initial dose ) depressive episodes associated bipolar disorder ( 2.5 ) oral combination olanzapine : 5 mg oral olanzapine 20 mg fluoxetine daily ( initial dose ) oral combination olanzapine : 2.5 mg oral olanzapine 20 mg fluoxetine daily ( initial dose ) treatment resistant depression ( 2.6 ) oral combination olanzapine : 5 mg oral olanzapine 20 mg fluoxetine daily ( initial dose ) lower less frequent used patients hepatic impairment , elderly , patients concurrent disease multiple concomitant medications ( 2.7 ) fluoxetine capsules olanzapine combination : adjustments made individual components according efficacy tolerability ( 2.5 , 2.6 ) fluoxetine monotherapy indicated treatment depressive episodes associated bipolar disorder treatment resistant depression ( 2.5 , 2.6 ) safety coadministration doses 18 mg olanzapine 75 mg fluoxetine evaluated adults ( 2.5 , 2.6 ) safety coadministration doses 12 mg olanzapine 50 mg fluoxetine evaluated children adolescents ages 10 17 ( 2.5 )",
    "warningsAndPrecautions": "fluoxetine capsules usp , 20 mg * opaque green cap/opaque white body , size ‘ 3 ’ hard gelatin capsule filled white off-white granular powder imprinted ‘ e ’ opaque green cap ‘ 91 ’ opaque white body black ink . ndc : 70518-1359-00 ndc : 70518-1359-01 ndc : 70518-1359-02 ndc : 70518-1359-03 ndc : 70518-1359-04 packaging : 30 1 bottle plastic packaging : 100 1 bottle plastic packaging : 30 1 blister pack packaging : 60 1 blister pack packaging : 90 1 bottle plastic * fluoxetine base equivalent . storage handling store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . preserve tight , light-resistant containers . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "using fluoxetine capsules olanzapine combination , also refer section package insert symbyax .",
    "indications_original": "Fluoxetine capsules are indicated for the treatment of:\n                  \n                  \n                     Acute and maintenance treatment of Major Depressive Disorder\n  \n   [see\n   \n    Clinical Studies (14.1)]\n  \n   .\n \n  \n                     Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD)\n  \n   [see\n   \n    Clinical Studies (14.2)]\n  \n   .\n \n  \n                     Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa\n  \n   [see\n   \n    Clinical Studies (14.3)]\n  \n   .\n \n  \n                     Acute treatment of Panic Disorder, with or without agoraphobia\n  \n   [see\n   \n    Clinical Studies (14.4)]\n  \n   .\n \n  \n                  \n                  \n                  Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of:\n                  \n                  \n                     Acute treatment of depressive episodes associated with Bipolar I Disorder.\n                     Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode).\n                  \n                  Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. \n  \n                     \n                          When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax\n  \n   ®.",
    "contraindications_original": "Indication Adult Pediatric MDD ( 2.1 ) 20 mg/day in am (initial dose) 10 to 20 mg/day (initial dose) OCD ( 2.2 ) 20 mg/day in am (initial dose) 10 mg/day (initial dose) Bulimia Nervosa ( 2.3 ) 60 mg/day in am Panic Disorder ( 2.4 ) 10 mg/day (initial dose) Depressive Episodes Associated with Bipolar I Disorder ( 2.5 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Oral in combination with olanzapine: 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) Treatment Resistant Depression ( 2.6 ) Oral in combination with olanzapine: 5 mg of oral olanzapine and 20 mg of fluoxetine once daily (initial dose) A lower or less frequent dosage should be used in patients with hepatic impairment, the elderly, and for patients with concurrent disease or on multiple concomitant medications ( 2.7 ) Fluoxetine capsules and olanzapine in combination: Dosage adjustments should be made with the individual components according to efficacy and tolerability ( 2.5 , 2.6 ) Fluoxetine monotherapy is not indicated for the treatment of Depressive Episodes associated with Bipolar I Disorder or treatment resistant depression ( 2.5 , 2.6 ) Safety of the coadministration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults ( 2.5 , 2.6 ) Safety of the coadministration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17 ( 2.5 )",
    "warningsAndPrecautions_original": "Fluoxetine Capsules USP, 20 mg* are opaque green cap/opaque off white body, size ‘3’ hard gelatin capsule filled with white to off-white granular powder and imprinted with ‘E’ on opaque green cap and ‘91’ on opaque off white body with black ink.\n                        NDC: 70518-1359-00\n                        NDC: 70518-1359-01\n                        NDC: 70518-1359-02\n                        NDC: 70518-1359-03\n                        NDC: 70518-1359-04\n                        PACKAGING: 30 in 1 BOTTLE PLASTIC\n                        PACKAGING: 100 in 1 BOTTLE PLASTIC\n                        PACKAGING: 30 in 1 BLISTER PACK\n                        PACKAGING: 60 in 1 BLISTER PACK\n                        PACKAGING: 90 in 1 BOTTLE PLASTIC\n                        \n                        *Fluoxetine base equivalent.\n                        Storage and Handling\n                        Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Preserve in tight, light-resistant containers.\n                        \n                        Repackaged and Distributed By:\n                        Remedy Repack, Inc.\n                        625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "When using\n                     fluoxetine capsules and olanzapine in combination, also refer to the Contraindications section of the package insert for Symbyax."
}